TP53 and breast neoplasm: In this study, we have shown that fresh, treatment-naïve organotypic human breast tumors closely recapitulating the human disease[22] can be stratified into two discrete subgroups that differ sharply in their response to doxorubicin with respect to proliferative status, p53 function and modulation of apoptosis.